García, MarilinaRedondo, MaximinoZarcos, IreneLouro, JavierRivas-Ruiz, FranciscoTéllez, TeresaPérez, DiegoMedina Cano, FranciscoMachan, KenzaDomingo, LaiaDel Mar Vernet, MariaPadilla-Ruiz, MariaCastells, XavierSala, Maria2023-05-032023-05-032022-04-012587-0831http://hdl.handle.net/10668/21636The aim of this study was to evaluate the existing survival rate and clinical-pathological differences among patients with breast cancer detected by mammographic screening. This multicenter cohort study examined 1,248 patients who took part in a national screening program for the early detection of breast cancer over an eight-year period. Of the two patient subgroups (interval and screening), we found significant differences in the distribution of prognostic factors, with interval cases presenting at a lower mean age (p = 0.002), with higher percentages of human epidermal growth factor receptor 2 (HER-2) or triple negative and lower percentages of luminal A or luminal B carcinomas (p = 0.001), advanced stages (p Our results highlight that breast tumors detected during the first screening round are frequently characterized by a more benign phenotype than the rest of the screening subgroups, which could be of help when stratifying the risk of death and selecting the best treatment option for each patient.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Breast cancerrisk factorsscreeningsurvivalresearch article35445174open access10.4274/ejbh.galenos.2022.2021-11-8PMC8987861https://doi.org/10.4274/ejbh.galenos.2022.2021-11-8https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987861/pdf